Will This Treatment Help Anacor’s Stock Soar?

  Google+  Twitter | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

MedicineShares of Anacor Pharmaceuticals (NASDAQ:ANAC) received a boost Friday after reporting positive trial results for a medicine designed to treat eczema — a type of chronic rash that causes inflammation and itching — in children and adolescents, which could prove be more effective than rival medications, reported MarketWatch.

After following a predominantly downward path this year, the stock gained as much as 32 percent, or $1.55, in morning trading on Friday, sending shares up to $6.39. With this increase, shares are up more than 66 percent from their $3.84 close on Wednesday.

The stock market is at 5-year highs! Discover the best stocks to buy in today’s market. CLICK HERE for Your Stock Investor Cheat Sheet NOW!

Anacor’s treatment, called AN2728 during the experimental phase, is currently in its second round of studies, and according to the recently-reported results, it improved the skin condition by 71 percent when the ointment was applied for a 28-day period. Phase three studies will begin by the end of the year…

When it hits the market, the treatment will compete with rival medications like Elidel, which Novartis (NYSE:NVS) sold to Stockholm-based Meda in 2011.

While rival treatments exist, the high level of effectiveness could help Anacor’s ointment generate $1 billion in annual global sales, as Wedbush Securities analyst Gregory Wade wrote in a note to clients, seen by MarketWatch. Based on this estimate, he raised his price target on the company’s shares from $10 to $20. “In addition to demonstrating a strong safety profile, [the ointment] appears to work rapidly, in just four weeks, compared to six weeks for Elidel, a key attribute for potential market success,” the analyst wrote.

Anacor

Don’t Miss: Shares of Titan Pharmaceuticals Jump on This FDA News.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business